AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (819.6 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

Circular RNA circEIF3C promotes intrahepatic cholangiocarcinoma progression and immune evasion via the miR-34a-5p/B7–H4 axis

Xiaoming Zhonga,1, Changxue Jib,1, Dabin Renc,1, Aiwu Ked, Zhiwen Yange( )
Department of Oncology Radiotherapy, Jiangxi Cancer Hospital, Nanchang, Jiangxi 330000, China
Department of Interventional Treatment, Songjiang District Central Hospital, Shanghai 201600, China
Department of Gastroenterology, Songjiang District Central Hospital, Shanghai 201600, China
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Department of Pharmacy, Songjiang District Central Hospital, Shanghai 201600, China

Xiaoming Zhong, Changxue Ji, and Dabin Ren contributed equally to this work.

Peer review under responsibility of Chongqing Medical University.

Show Author Information

References

【1】
【1】
 
 
Genes & Diseases
Pages 370-372

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Zhong X, Ji C, Ren D, et al. Circular RNA circEIF3C promotes intrahepatic cholangiocarcinoma progression and immune evasion via the miR-34a-5p/B7–H4 axis. Genes & Diseases, 2023, 10(2): 370-372. https://doi.org/10.1016/j.gendis.2022.05.005

631

Views

6

Downloads

14

Crossref

12

Web of Science

13

Scopus

0

CSCD

Received: 29 January 2022
Published: 19 May 2022
© 2022 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).